- Conditions
- Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
- Interventions
- anecortave acetate
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cataract
- Interventions
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye Disease
- Interventions
- Systane Ultra, Saline solution, Maxidex
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cataract
- Interventions
- Dexamethasone Drug Delivery System, Placebo Drug Delivery System
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Limbal Stem Cell Deficiency
- Interventions
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Procedure · Biological
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
- Drug
- Lead sponsor
- Nicole Fram M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glaucoma
- Interventions
- Triesence, balanced salt solution BSS
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
- Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Cataract, Retinal Edema, Inflammation
- Interventions
- Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
- Drug
- Lead sponsor
- Melissa Toyos
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Inflammation Corneal, Pain, Postoperative
- Interventions
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
- Drug
- Lead sponsor
- Oculis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
- Conditions
- Cataract, Inflammation
- Interventions
- BOL-303242-X, Vehicle for BOL-303242-X
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Inflammation Symptoms, Eye Dryness, Eye Health
- Interventions
- Eye Empower
- Dietary Supplement
- Lead sponsor
- Bio Nature Health
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ocular Inflammation
- Interventions
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Cataract, Pain, Ocular Inflammation
- Interventions
- Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
- Conditions
- Meibomian Gland Dysfunction, Evaporative Dry Eye
- Interventions
- Dexamethasone, 0.4mg, Prednisone acetate, Control
- Drug · Other
- Lead sponsor
- Warrenville Eyecare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Warrenville, Illinois
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- KSI-101, Sham Comparator
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 47 more
- Conditions
- Postoperative Complications, Inflammation, Glaucoma, Open-Angle
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
- Interventions
- Rinsada
- Device
- Lead sponsor
- Rinsada
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Retinal Detachment, Rhegmatogenous Retinal Detachment
- Interventions
- Lamivudine 300 MG, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cataract
- Interventions
- Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference)
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland